LivaNova PLC (LIVN) Director Sells $83,320.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $83.32, for a total value of $83,320.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Daniel Jeffrey Moore also recently made the following trade(s):

  • On Tuesday, January 16th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The shares were sold at an average price of $82.15, for a total value of $82,150.00.
  • On Friday, December 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The shares were sold at an average price of $80.80, for a total value of $80,800.00.

Shares of LivaNova PLC (NASDAQ LIVN) opened at $85.85 on Friday. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. LivaNova PLC has a fifty-two week low of $46.34 and a fifty-two week high of $88.56. The stock has a market capitalization of $4,139.00, a PE ratio of 73.38, a PEG ratio of 2.55 and a beta of 0.83.

Several analysts have commented on LIVN shares. ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Needham & Company LLC lifted their price target on LivaNova from $83.00 to $89.00 and gave the company a “buy” rating in a report on Friday, November 3rd. Jefferies Group boosted their target price on LivaNova from $80.00 to $91.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Piper Jaffray Companies reiterated a “buy” rating and set a $85.00 target price on shares of LivaNova in a report on Friday, November 3rd. Finally, BTIG Research reiterated a “hold” rating on shares of LivaNova in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $79.71.

Several large investors have recently modified their holdings of the company. PNC Financial Services Group Inc. grew its holdings in shares of LivaNova by 9.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after purchasing an additional 153 shares during the period. Strs Ohio lifted its position in LivaNova by 2.9% during the 4th quarter. Strs Ohio now owns 21,100 shares of the company’s stock worth $1,686,000 after acquiring an additional 600 shares in the last quarter. Tyers Asset Management LLC lifted its position in LivaNova by 22.0% during the 4th quarter. Tyers Asset Management LLC now owns 3,376 shares of the company’s stock worth $270,000 after acquiring an additional 608 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in LivaNova by 9.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,274 shares of the company’s stock worth $578,000 after acquiring an additional 643 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in LivaNova by 1.2% during the 4th quarter. Teachers Advisors LLC now owns 88,299 shares of the company’s stock worth $7,057,000 after acquiring an additional 1,043 shares in the last quarter. Institutional investors and hedge funds own 88.53% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “LivaNova PLC (LIVN) Director Sells $83,320.00 in Stock” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://ledgergazette.com/2018/02/18/livanova-plc-livn-director-sells-83320-00-in-stock.html.

LivaNova Company Profile

LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply